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Abstract
BACKGROUND: Activated forms of RAS increase both in breast cancer and in cell lines in the presence of estimated 
glomerular filtration rate (EGFR) or HER2 expression. HRAS oncoproteins play an important role in enhancing 
the proliferation and resistance of breast cancer tumor cells to apoptosis. A number of studies have shown a 
significant decrease in EGFR expression after neoadjuvant chemotherapy, which has been clinical, manifested by 
an improvement in immediate efficacy and an increase in overall and relapse-free breast cancer survival rates.
AIM: The aim of the study was to study relapse-free survival depending on the expression of the H-RAS oncoprotein 
in patients with breast cancer who received different treatment regimens for the farnesyltransferase inhibitor.
METHODS: H-RAS status was assessed by immunohistochemistry.
RESULTS: A comparative analysis of patients with negative expression of H-RAS oncoproteins showed a statistically 
significant increase in relapse-free survival in the subgroups who received neoadjuvant chemotherapy according 
to the AC regimen (adriablastin + cyclophosphamide) and AC + arglabin, compared with monotherapy by arglabin: 
Kruskal–Wallis= 12.56, where p = 0.001. A comparative analysis of patients with positive expression of H-RAS 
showed that in the subgroups treated with arglabin and AC+arglabin, there was a statistically significant increase in 
relapse-free survival compared with the AC subgroup: Kruskal–Wallis = 10.96, where p = 0.004. It was established 
that the positive expression of H-RAS negatively affects not only the direct effectiveness of neoadjuvant therapy but 
also worsens the rates of relapse-free survival. However, in patients with positive H-RAS expression who received 
arglabin in monotherapy, there was a statistically significant increase in relapse-free survival up to 16.5 ± 1.1 months 
compared with the standard AC regimen (13.5 ± 1.1 months) (р ˂ 0.05), the addition of arglabin to the standard AC 
regime also increased this indicator to 16.4 ± 1.2 months (р ˂ 0.05).
CONCLUSION: These results may indicate the clinical applicability of determining H-RAS as a prognostic factor for 
relapse-free survival in breast cancer.
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Introduction
The high heterogeneity of breast cancer is a 
prerequisite for a more in-depth study of the molecular 
mechanisms of functioning of malignant cells, the 
identification of factors affecting their growth rate, 
the ability to invasion and metastasis that affect the 
prognosis of the disease [1], [2], [3], [4], [5].
Studies of the relationship of H-RAS oncogene 
expression with the clinical and pathological parameters 
of breast cancer have demonstrated high expression of 
this oncogene in patients with an aggressive course 
of the disease and frequent metastasis [6], [7]. When 
comparing H-RAS expression with the clinical and 
pathological parameters of breast cancer and gastric 
cancer, it was shown that high expression in patients 
with breast cancer is often associated with tumor 
aggressiveness [8], [9], [10]. Conducted studies have 
shown that the expression of H-RAS protein can be 
used as a marker for predicting the progression of 
breast cancer, as well as to stratify patients depending 
on the expression status and the risk of metastasis for 
pre-operative chemotherapy courses [11].
Blocking RAS signaling, inhibition of H-RAS 
in breast cancer is a rather promising direction 
in therapy. Significant efforts have been made to 
develop pharmacological agents that block RAS 
function [12], [13], [14], [15], [16].
The first phase of the QLNC120 study, a new 
inhibitor of estimated glomerular filtration rate (EGFR) 
and HER2 kinase (study registration: NCT01931943), 
in previously treated patients with HER2-positive 
breast cancer, showed that nine out of fifteen patients 
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(60%) had a mutation in H-RAS exon. Patients with the 
H-RAS mutation achieved higher disease progression-
free survival rates (24.9 vs. 12.9 weeks, p = 0.023) 
against the background of QLNC120 application. 
H-RAS mutation correlated with the antitumor activity 
of QLNC120 [17].
Farnesyltransferase inhibitors also block the 
growth of wild-type RAS breast cancer xenografts MCF-7, 
causing a cell-cycle block in the G2/M or Gl phase 
and inducing apoptosis [18], [19]. Phase II of a clinical 
study of the combination of farnesyltransferase inhibitor 
tipifarnib+capecitabine combination in 63 patients with 
a breast cancer diagnosis, after progressing to therapy 
with anthracyclines and taxanes, showed an insignificant 
response rate of up to 10% and a median of a relapse-
free period of 2.6 months and the median overall 
survival of 11.4 months. This combination was superior 
to capecitabine therapy in mono mode but inferior in 
toxic manifestations since 68% of patients required dose 
modification that was associated with tipifarnib [20].
The use of farnesyltransferase inhibitor arglabin 
during radiation therapy reduced the tumor volume by 
5.5 times with intratumoral administration of the drug, 
by 8.5 times with intravenous administration, and in the 
comparison group, the tumor decreased only by 2.8 
times. The use of arglabin significantly more often leads 
to pronounced radiation pathomorphism of the tumor, 
corresponding to the III-IV degree: With intratumoral 
administration in 64% of cases, with intravenous 
administration in 50%, and with radiation treatment in 
37%. The intravenous administration of arglabin during 
radiation therapy has a positive effect on the long-term 
results of the complex treatment of patients with locally 
advanced breast cancer; the indicators of 2 and 3-year 
survivals were 93% and 90%, respectively, which is 
significantly higher than when radiotherapy alone (63% 
and 53%, respectively) [21], [22].
Preclinical and clinical studies indicate that 
farnesyltransferase inhibitors are active in breast 
cancer with increased expression of the H-RAS 
oncogene. Thus, a study of the mechanism of the effect 
of these drugs on signaling pathways contributed to 
the identification of a new therapeutic target for the 
treatment of breast cancer, as well as improved rates of 
relapse-free survival.
The aim of this study was to study relapse-free 
survival depending on the expression of the H-RAS 
oncoprotein in patients who received different treatment 
regimens with a farnesyltransferase inhibitor.
Materials and Methods
The criteria for inclusion in the study were: 
Morphological samples of patients with histological 
verification, Stage II and III of the disease, T2N1-2M0, 
and T3N0-2M0. A group of 100 patients with a diagnosis 
of locally advanced breast cancer was recruited between 
January 2012 and February 2014. Their age ranged 
from 29 to 78 years, and the average age was 59 years 
(56 ± 1.2). The clinical-stage has been described based 
on the TNM International Classification of Malignant 
Tumors (7th Edition). The study was approved by 
the Ethics Committee of the Medical University of 
Karaganda (Karaganda, Kazakhstan).
Immunohistochemical determination of the 
expression of H-RAS oncoprotein was determined in 
samples of archival histological material of patients with 
breast cancer before treatment and after. Expression 
was evaluated independently by two researchers. A 
positive reaction was considered positive staining on 
the membrane and in the cytoplasm of tumor cells. 
The percentage of positively stained cells and staining 
intensity was evaluated. Positive cell percentage: 
<10%–0; 10–50%–1; 51–80%–2; >81%–3. Reaction 
rate: lack of reaction – 0 points; weak reaction – 1 point; 
moderate reaction – 2 points; pronounced reaction – 3 
points. IRS rating scale: 0–2 points – negative reaction; 
3–4 points – weak reaction; 6–8 points – moderate 
reaction; 9–12 points – a high degree reaction. Coloring 
on the membrane and cytoplasm of tumor cells was 
considered a positive reaction. Patients with a positive 
reaction were included in the study group. As a negative 
immunophenotype was considered the expression 
of H-RAS with an IRS point (0–2 points), in ≤20% of 
stained tumor cells. Patients with negative expression 
were included in the comparison group.
All patients received comprehensive 
treatment, including four courses of neoadjuvant drug 
therapy, surgical treatment in the amount of radical 
mastectomy, or radical sectoral resection of the breast. 
After evaluating the drug pathomorphism of the tumor, 
patients underwent four courses of adjuvant drug 
chemotherapy and radiation therapy, if indicated. In 
hormone-dependent cancer, adjuvant hormone therapy 
was performed.
A blind randomized study was conducted to 
select a neoadjuvant therapy regimen and assign it to 
treatment groups.
Drug therapy was carried out according to the 
following schemes: 
Polychemotherapy according to scheme – 
doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 
intravenously on 1 day of every 21-day cycle.
Monotherapy with drug arglabin 370 mg/m2 
from 1 to 7 days of every 21 day cycle was prescribed. 
Drug therapy (chemotherapy according to 
the AC + arglabin regimen) doxorubicin 60 mg/m2, 
cyclophosphamide 600 mg/m2 intravenous 1 day, and 
arglabin 370 mg/m2 from 1 to 7 days of every 21-day 
cycle.
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Statistical analysis
For a comprehensive assessment of treatment 
results, a relapse-free survival analysis was used. In 
this work, we used the dynamic actuarial method for 
calculating the relapse-free survival, according to 
Kaplan–Meier using the “Statistica 10.0” program. An 
indicator of a statistically significant difference was the 
level p < 0.05.
Results and Discussion
All 100 patients were women with an average 
age of 59 years (56 ± 1.2). The average follow-up 
period was 12 months. H-RAS expression was 
evaluated in 200 samples of tumor tissue before and 
after neoadjuvant breast cancer therapy. According to 
the classification criteria (Table 1), a total of 45 tumor 
samples (45%) were positive for the expression of 
H-RAS oncoproteins (on the IRS scale from 3 to 12 
points) before treatment and 35 tumor samples (35%) 
after treatment (Table 1).
Table 1: The level of expression of H-RAS depending on 
therapy
The expression level of H-RAS oncoprotein according to IRS scale (n = 100)
Therapy Strong expression 
(M ± SD)
Moderate expression 
(M ± SD)
Negative expression 
(M ± SD)
Before treatment 32 (78.4 ± 8.7) 13 (43.0 ± 6.4) 55 (13.50 ± 5.2)
After treatment 25 (75.4 ± 6.9) 10 (41.2 ± 3.7) 65 (14.50 ± 4.1)
A study of relapse-free survival showed that 
in the comparison group with negative expression of 
H-RAS, the median relapse-free survival was 33.0 ± 1.1 
months (Figure 1).
Figure 1: Relapse-free survival of patients diagnosed with breast 
cancer and negative expression of H-Ras
A comparative analysis in patients with 
negative expression of H-RAS oncoproteins showed a 
statistically significant increase in relapse-free survival 
in subgroups who received neoadjuvant chemotherapy 
according to the AC and AC+Arglabin regimen compared 
with arglabin monotherapy: Kruskal–Wallis=12.56, 
where p = 0.001 (Table 2 and Figure 2).
The use of arglabin in combination with 
the standard AC regimen in patients with negative 
expression of H-RAS did not improve relapse-free 
survival rates (р = 0.001).
Figure 2: Comparative analysis of relapse-free survival in patients of 
the comparison group with negative expression of H-Ras
The neoadjuvant therapy with arglabin in 
patients with negative expression of H-RAS in terms of 
relapse-free survival was less effective compared to the 
standard AC regimen.
Relapse-free survival in the study group of 
patients diagnosed with breast cancer and positive 
expression of H-RAS who received neoadjuvant drug 
therapy was 16.0 ± 1.0 months (Figure 3).
As can be seen in Figure 3, disease-free 
survival was 16.0 ± 1.0 months.
Figure 3: Relapse-free survival of patients diagnosed with breast 
cancer and positive expression of H-Ras who received neoadjuvant 
drug therapy
Table 2: Relapse-free survival rates for patients diagnosed with 
breast cancer and negative expression of H-RAS who received 
neoadjuvant therapy
Subgroup of neoadjuvant drug therapy Relapse-free survival
АС (n = 23) 33.0 ± 5.19*
АС+Arglabin (n = 18) 34.0 ± 5.4*
Arglabin (n = 14) 25.4 ± 3.67
*Reliability p ˂ 0.05 compared with Arglabin.
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A comparative analysis in patients with positive 
expression of H-RAS showed that in the subgroups of 
patients treated with Arglabin and AC+Arglabin, there 
was a statistically significant increase in relapse-free 
survival compared with the AC subgroup: Kruskal-
Wallis = 10.96, where p = 0.004 (Table 3 and Figure 4).
Table 3: Relapse-free survival rates for breast cancer patients 
with positive H-RAS expression who received neoadjuvant 
therapy
Subgroup of neoadjuvant drug therapy Relapse-free survival
АС (n = 16) 13.5 ± 2.75*
АС+Arglabin (n = 12) 16.4 ± 2.10*
Arglabin (n = 17) 16.5 ± 2.03
*Reliability p ˂ 0.05 compared with Arglabin.
Figure 4: Comparative analysis of relapse-free survival in patients of 
the study group with positive expression of H-Ras
A comparative analysis showed that in patients 
diagnosed with breast cancer and negative status of 
H-RAS, relapse-free survival rates were statistically 
higher than in patients with positive H-RAS, p = 0.001, 
according to the Log-Rank Test (Figure 5).
Figure 5: Relapse-free survival of patients with breast cancer who 
received neoadjuvant drug therapy
A comparative analysis of breast cancer 
patients who received neoadjuvant therapy is presented 
in Table 4 and Figure 6.
A comparative analysis of relapse-free 
survival indicators showed that in the comparison 
group the indicators were statistically significantly 
higher than in the study group: Mann–Whitney U Test 
= 15.11; p = 0.03.
Figure 6: Comparative analysis of relapse-free survival of patients 
with breast cancer in the study groups
Subgroup comparative analysis also showed 
that in patients with negative expression of H-RAS in 
all subgroups, regardless of the neoadjuvant therapy 
regimen, the rates of relapse-free survival were 
statistically higher than in the group with positive H-RAS 
expression.
It has also been established that positive 
expression of H-RAS worsens relapse-free survival 
indicators. However, in patients with positive H-RAS 
expression who received arglabin, there was a 
statistically significant increase in relapse-free 
survival up to 16.5 ± 1.1 months compared with the 
standard AC regimen (13.5 ± 1.1 months) (р = 0.02), 
the use of arglabin in combination with the standard 
AC regime also increased this indicator to 16.4 ± 1.2 
months (р ˂ 0.05).
Discussion
One of the most important issues in oncology 
over the years is the problem of predicting the course 
of malignant neoplasms to possibly predict the 
development of various forms of disease progression. 
In this regard, the search for additional markers to 
assess the risk of tumor recurrence remains relevant 
and today. The role of RAS genes in malignant tumors is 
Table 4: Relapse-free survival rates for patients diagnosed with 
breast cancer who received neoadjuvant therapy, depending 
on the treatment regimen
Comparison group Study group
Treatment regimen Relapse-free 
survival
Treatment regimen Relapse-free 
survival
АС (n = 23) 33.0 ± 5.19* АС (n = 16) 13.5 ± 2.75*
АС+Arglabin (n = 18) 34.0 ± 5.4* АС+ Arglabin (n = 12) 16.4 ± 2.10*
Arglabin (n = 14) 25.4 ± 3.67 Arglabin (n = 17) 16.5 ± 2.03
Total (n = 55) 33.0 ± 10.29* Total (n = 45) 16.0 ± 1.0*
*Reliability p ˂ 0.01 compared with the comparison group.
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multifaceted since they are involved in the proliferation 
of various tumor cells. Modern targeted therapy already 
has some success with RAS-associated colorectal 
cancer, melanoma, and pancreatic cancer [23]. For 
patients with breast cancer, studies on the role of RAS 
genes are ongoing, especially in the last few years.
Demetrios et al. conducted an 
immunohistochemical study of 75 cases of benign 
and malignant diseases of the mammary gland and 
determined the expression of p21 H-RAS protein. Most 
complex cystic diseases, hyperplastic fibroadenomas, 
and all types of breast carcinomas showed a high 
expression of p21. These results show that increased 
expression of p21 H-RAS may play an important role in 
the development of certain precancerous and malignant 
affections of mammae [24].
When studying the expression of H-RAS 
(p21ras – monoclonal antibody 235–1.7.1) in 297 
patients with breast carcinoma, 58% of H-RAS positive 
tumor cells were detected. It was also demonstrated 
that high expression of H-RAS oncoproteins (p21ras) 
correlated with the largest tumor tissue size, the 
presence of regional metastasis, and a high proliferative 
activity index Ki-67, as well as tumors with negative 
hormonal status. The detection of positive expression 
of H-RAS (p21ras) was also associated with a more 
favorable prognosis in patients without metastases in 
regional lymph nodes [25].
The researchers also showed that the high 
frequency of expression of Ras and Her2neu proteins in 
breast cancer is associated with disease progression [26].
Numerous studies of H-RAS proteins in breast 
cancer have shown that these biological structures play 
an important role in the proliferation and progression of 
breast cancer [27], [28], [29].
However, to date, the role of H-RAS expression 
in breast cancer has not been fully studied, and thus its 
further study is an urgent problem.
In our study, it was demonstrated that positive 
H-RAS expression worsens relapse-free survival 
indicators in patients with breast cancer compared 
with a group of patients with negative H-RAS status. It 
was found that in patients with positive H-RAS H-RAS 
expression who received drug “Arglabin,” a statistically 
significant increase in relapse-free survival was observed 
up to 16.5 ± 1.1 months compared with the standard 
AC regimen (13.5 ± 1.1 months), where p ˂ 0.05. The 
combination of arglabin + standard AC regime also 
increased this indicator to 16.4 ± 1.2 months (р ˂ 0.05).
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